Clinical Trials Logo

Clinical Trial Summary

Menitorix is a combined Hib conjugate and meningococcal C conjugate vaccine made by GlaxoSmithKline. It is currently licensed and recommended as a booster vaccination for UK children in the second year of life.

It is important that staff who have a potential occupational exposure to infectious disease are afforded protection where possible. The licensure and availability of Menitorix provides the opportunity to vaccinate such staff.

Immune responses that are indicative of protection have been established for both Hib and meningococcal C disease. It is therefore proposed that the immune responses of those laboratory staff taking part be measured as data currently available following Menitorix vaccination is in naïve children and adults. This study will also allow us to provide occupational healthcare to laboratory workers.

Participation in the study would be offered to all those staff considered to be at occupational health risk of Hib or meningococcal C disease at the Manchester HPA site. This will be a single group study in that everyone enrolled will receive a single dose of Menitorix and will have blood collected prior to and 4-6 weeks following vaccination.

Assessment of whether protective levels of antibody have been achieved will be made using the blood sample taken 4-6 weeks after vaccination. Extra dose(s) will be offered to any subjects whose levels are not considered to confer protection as described later in this protocol. Subjects receiving and extra vaccination will be offered and a further blood test 4-6 weeks later to allow antibody levels to be checked again.


Clinical Trial Description

Menitorix is a combined Hib conjugate and meningococcal C conjugate vaccine made by GlaxoSmithKline. It is currently licensed and recommended as a booster vaccination for UK children in the second year of life.

It is important that staff who have a potential occupational exposure to infectious disease are afforded protection where possible [HPA Occupational Health Policy [Appendix 1]; HSE Safe working and the prevention of infection in clinical laboratories and similar facilities, 2003]. The licensure and availability of Menitorix provides the opportunity to vaccinate such staff.

Immune responses that are indicative of protection have been established for both Hib and meningococcal C disease [Andrews et al., 2003; Kayhty et al., 1983]. It is therefore proposed that the immune responses of those laboratory staff taking part be measured as data currently available following Menitorix vaccination is in naïve children and adults [Tejedor et al., 2006a and b; Carmona et al., 2006; Habermehl et al., 2006; Pace et al., 2006]. This study will also allow us to provide occupational healthcare to laboratory workers.

Laboratory staff at Manchester have not received a Hib vaccine although they have received a number of meningococcal vaccines with the majority having received their meningococcal serogroup C conjugate vaccine in 1999. Certain staff would have received bivalent meningococcal A and C prior to the conjugate vaccine which has recently been demonstrated to hinder the induction of immunological memory by the conjugate vaccine [Vu et al., 2006]. Following the conjugate vaccine many staff have since received a quadrivalent A/C/Y/W135 polysaccharide vaccine in the following seven years, but little is known about the duration of protection in this age group.

Receiving a polysaccharide vaccine following a conjugate does induce an elevated antibody response but it is known that polysaccharide vaccination does not generate memory B cells and can result in the loss of the ability to mount subsequent memory antibody responses, as was observed by MacLennan et al. for Neisseria meningitidis group C anticapsular antibody responses [MacLennan et al., 2001]. The clinical importance of loss of immunological memory or induction of antibody hyporesponsiveness, is unknown. However, in addition to dampening antibody responses to a subsequent immunisation, a delay or impaired serum antibody response upon encountering an encapsulated pathogen could theoretically increase susceptibility to developing disease. Such a mechanism may explain the higher rate of otitis media observed after administration of 23-valent pneumococcal polysaccharide vaccine to Dutch children primed with a 7-valent pneumococcal polysaccharide protein conjugate vaccine as compared with the rate in controls given hepatitis B vaccine (P=0.0001) [Veenhoven et al., 2003]. In contrast, during the six months between the conjugate vaccination and booster there was a trend in favor of fewer episodes of otitis in the pneumococcal-vaccinated group.

It appears that staff will benefit from both the Hib and serogroup C conjugate vaccinations.

Assessments in this study:

Participation in the study would be offered to all those staff considered to be at occupational health risk of Hib or meningococcal C disease at the Manchester HPA site. The maximum number of participants would therefore be 30. This will be a single group study in that everyone enrolled will receive a single dose of Menitorix and will have blood collected prior to and 4-6 weeks following vaccination.

Local anaesthetic cream will be offered to minimise discomfort of the blood tests and fully trained staff will carry out all procedures.

Assessment of whether protective levels of antibody have been achieved will be made using the blood sample taken 4-6 weeks after vaccination. Extra dose(s) will be offered to any subjects whose levels are not considered to confer protection as described later in this protocol. Subjects receiving and extra vaccination will be offered and a further blood test 4-6 weeks later to allow antibody levels to be checked again.

Samples will be sent to collaborating laboratories of the National Vaccine Evaluation Consortium for assessment of responses to vaccinations. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00503165
Study type Interventional
Source Public Health England
Contact
Status Completed
Phase Phase 4
Start date July 2007
Completion date August 2007

See also
  Status Clinical Trial Phase
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Recruiting NCT05996549 - Cost-effectiveness of the Influenza Vaccination Phase 4
Completed NCT04323137 - Encouraging Flu Vaccination Among High-Risk Patients Identified by ML N/A
Completed NCT01224301 - School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities N/A
Completed NCT00169858 - Long Term Immunogenicity Study of Engerix-B Vaccine in 10 Year Old Children and the Effect of Booster Injections Phase 4
Completed NCT05509283 - Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications N/A
Completed NCT02907580 - Influenza Vaccine Attitudes, Intent, and Receipt: Pediatric N/A
Recruiting NCT06160999 - Improving Uptake of Pediatric Vaccines Through Religious Conferences and Vaccines-in-a-van in Aceh, Indonesia N/A
Recruiting NCT03875703 - Post-Vaccination Biological Collection
Completed NCT03287830 - Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine N/A
Completed NCT02907645 - Influenza Vaccine Randomized Educational Trial: Adult N/A
Completed NCT03220555 - Efficacy of the Buzzy® Device on the Prevention of Health Care Induced Pediatric Pain in a Vaccination Center N/A
Withdrawn NCT05023512 - Understanding Public Attitudes Towards the COVID-19 Vaccination N/A
Recruiting NCT02937428 - To Look or Not to Look at the Needle During Vaccination Phase 3
Completed NCT00813319 - Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females Phase 3
Completed NCT03104790 - Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls Phase 4
Completed NCT04780867 - Psychological and Lifestyle Factors on Health Outcomes N/A
Completed NCT03239795 - Promoting Influenza Vaccination In General Practice Waiting Rooms N/A